Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 96% Improvement Relative Risk Mortality (b) 95% Hospitalization 88% Hospitalization (b) 89% c19early.org/pl Hammond et al. NCT04960202 Paxlovid RCT EARLY TREATMENT Is early treatment with paxlovid beneficial for COVID-19? Double-blind RCT 2,085 patients in multiple countries Lower mortality (p=0.00047) and hospitalization (p<0.0001) Hammond et al., New England J. Medicine, doi:10.1056/NEJMoa2118542 Favors paxlovid Favors control
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond et al., New England Journal of Medicine, doi:10.1056/NEJMoa2118542, NCT04960202 (history)
Hammond et al., Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2118542, NCT04960202
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
EPIC-HR RCT, 1,039 higher risk patients treated with paxlovid (PF-07321332 + ritonavir) and 1,046 control patients, showing significantly lower mortality and hospitalization with treatment. NCT04960202 (history).
risk of death, 96.0% lower, RR 0.04, p < 0.001, treatment 0 of 1,039 (0.0%), control 12 of 1,046 (1.1%), NNT 87, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), within 5 days.
risk of death, 94.8% lower, RR 0.05, p = 0.002, treatment 0 of 697 (0.0%), control 9 of 682 (1.3%), NNT 76, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), within 3 days.
risk of hospitalization, 87.6% lower, RR 0.12, p < 0.001, treatment 8 of 1,039 (0.8%), control 65 of 1,046 (6.2%), NNT 18, within 5 days.
risk of hospitalization, 88.9% lower, RR 0.11, p < 0.001, treatment 5 of 697 (0.7%), control 44 of 682 (6.5%), NNT 17, within 3 days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hammond et al., 16 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 12 authors, average treatment delay 2.93 days, trial NCT04960202 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Abstract: T h e n e w e ng l a n d j o u r na l o f m e dic i n e Original Article Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 Jennifer Hammond, Ph.D., Heidi Leister‑Tebbe, B.S.N., Annie Gardner, M.P.H., M.S.P.T., Paula Abreu, Ph.D., Weihang Bao, Ph.D., Wayne Wisemandle, M.A., MaryLynn Baniecki, Ph.D., Victoria M. Hendrick, B.Sc., Bharat Damle, Ph.D., Abraham Simón‑Campos, M.D., Rienk Pypstra, M.D., and James M. Rusnak, M.D., Ph.D., for the EPIC-HR Investigators*​​ A BS T R AC T BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS We conducted a phase 2–3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19–related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTS A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19–related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], −9.04 to −3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths. Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of −5.81 percentage points (95% CI, −7.78 to −3.84; P<0.001; relative risk reduction, 88.9%). All 13 deaths occurred in the placebo group. The viral load was lower with nirmaltrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of −0.868 log10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms. The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%). Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.). Dr. Hammond can be contacted at ­jennifer​ .­hammond@​­pfizer​.­com, or at Pfizer,..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit